Kadcycla (T-DM1) is too expensive to use

2015 Research

Remember when Herceptin was a wonder drug. Well, HER-2 breast cancer fought back.

We have covered the new version Kadcycla before – it’s also known as TDM-1. It is used for patients with advanced breast cancer where Herceptin has stopped working and supposedly gives them 6 months of extra life. But, it is very expensive. For the few, it costs 90,000 a year – both NICE and the Cancer Fund have rejected it.

The powers that be are trying to find a cheaper generic drug.


2015 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.